JP4984033B2 - 重炭酸塩含有薬液を充填した容器収納体 - Google Patents
重炭酸塩含有薬液を充填した容器収納体 Download PDFInfo
- Publication number
- JP4984033B2 JP4984033B2 JP2006133641A JP2006133641A JP4984033B2 JP 4984033 B2 JP4984033 B2 JP 4984033B2 JP 2006133641 A JP2006133641 A JP 2006133641A JP 2006133641 A JP2006133641 A JP 2006133641A JP 4984033 B2 JP4984033 B2 JP 4984033B2
- Authority
- JP
- Japan
- Prior art keywords
- chemical solution
- container
- bicarbonate
- carbon dioxide
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 155
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 title claims description 76
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 156
- 239000001569 carbon dioxide Substances 0.000 claims description 78
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 78
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 60
- 239000001301 oxygen Substances 0.000 claims description 60
- 229910052760 oxygen Inorganic materials 0.000 claims description 60
- 239000007789 gas Substances 0.000 claims description 59
- 238000003860 storage Methods 0.000 claims description 52
- 238000011049 filling Methods 0.000 claims description 41
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 36
- 239000005022 packaging material Substances 0.000 claims description 25
- 229920003023 plastic Polymers 0.000 claims description 16
- 239000004033 plastic Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 144
- 230000000052 comparative effect Effects 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000005587 bubbling Effects 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000006096 absorbing agent Substances 0.000 description 7
- -1 chlorine ions Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 239000008155 medical solution Substances 0.000 description 6
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003635 deoxygenating effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012603 secondary packaging material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003113 alkalizing effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 206010027417 Metabolic acidosis Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000011232 storage material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229960002337 magnesium chloride Drugs 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940026110 carbon dioxide / nitrogen Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- CHFUHGDBYUITQJ-UHFFFAOYSA-L dipotassium;2,3-dihydroxypropyl phosphate Chemical compound [K+].[K+].OCC(O)COP([O-])([O-])=O CHFUHGDBYUITQJ-UHFFFAOYSA-L 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000011600 potassium glycerophosphate Substances 0.000 description 1
- 235000000491 potassium glycerophosphate Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 239000001415 potassium malate Substances 0.000 description 1
- SVICABYXKQIXBM-UHFFFAOYSA-L potassium malate Chemical compound [K+].[K+].[O-]C(=O)C(O)CC([O-])=O SVICABYXKQIXBM-UHFFFAOYSA-L 0.000 description 1
- 235000011033 potassium malate Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1668—Details of containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/168—Sterilisation or cleaning before or after use
- A61M1/1686—Sterilisation or cleaning before or after use by heat
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Examining Or Testing Airtightness (AREA)
- Packages (AREA)
Description
したがって、重炭酸塩を含有する薬液を充填した容器を、ガス非透過性の外包材(収納体)で包装して、炭酸ガスの放出による薬液の変化を防止することが一般的に行われている。
ピンホール検知の代表例としては、ピンホールの発生により、大気中から収納体内部に侵入してきた酸素を検知する酸素検知剤が知られており、実際に使用されている。ただし、酸素検知剤を導入するにあたっては、包装内部を0.1%以下の酸素濃度としておく必要があり、実質的に脱酸素剤の併用が必須である(例えば、特許文献2)。
かかる脱酸素剤は、炭酸ガスの発生並びに吸収といった本来の酸素吸収性能以外の性質が排除された脱酸素剤である。
したがって、薬液自体の重炭酸イオン濃度の変動が無く、副作用の発生のない、安定した重炭酸塩を含有する薬液が提供される。
そのような脱酸素剤としては、炭素−炭素不飽和結合を有する架橋高分子化合物を主成分とするものであり、例えば、特開平11−347400号公報に開示されている脱酸素剤を挙げることができる。
理論的には、平衡状態における薬液のpHと炭酸ガス濃度は、ほぼ直線の相関関係を示す。なお、上記pHの範囲内及び炭酸ガス濃度の範囲内であっても、より好ましくは、炭酸ガス濃度との平衡を確保するpHが6.8〜7.1で、炭酸ガス濃度が9〜19v/v%程度であるのがよい。
次いで、薬液の濾過を行いガス透過性のプラスチック製容器に所望量の薬液の充填を行うことにより、重炭酸塩を含有する薬液充填容器が調製される。また、別法として、窒素ガスによる加圧・送液により、所望量の薬液の充填を行うことにより、ヘッドスペースの酸素濃度を減らした、重炭酸塩を含有する薬液充填容器が調製される。
なお、この段階において、薬液のpHは、若干の上昇をみる。
実施例1:
下記表1に記載の組成に従って、各成分を常温で適量の蒸留水に溶解し、溶液中に炭酸ガスをバブリングし、pHを6.5とし、0.22μmのメンブランフィルターで濾過した。濾液をポリエチレン製のプラスチック容器に500mLずつ充填し、当該容器内の空間部(ヘッドスペース)を約50mLにして閉塞し、105℃/25分で高圧蒸気滅菌を行った。
得られた薬液を充填した容器を、ガス不透過性外包材からなる二次包材である収納体に入れ、炭素−炭素不飽和結合を有する架橋高分子化合物を主成分とする脱酸素剤[エージレス(登録商標)GP:三菱瓦斯化学社製]及び酸素検知剤を封入した後、この薬液充填容器と二次包材の空間部を窒素で置換して、収納体を製造した。
上記実施例1において、脱酸素剤をエージレスGPに代えて炭酸ガスを吸収する鉄粉系の脱酸素剤であるエージレス(登録商標)ZP(三菱瓦斯化学社製)を使用した点を除き、実施例1と同様にして、比較例1の収納体を製造した。
上記実施例1において、脱酸素剤及び酸素検知剤を使用しなかった点を除き、実施例1と同様にして、比較例2の収納体を製造した。
上記実施例1において、炭酸ガスのバブリングによるpH調整でpHを6.8とした点を除き、実施例1と同様にして、実施例2の収納体を製造した。
上記実施例1において、炭酸ガスのバブリングによるpH調整でpHを6.8とした点、及び脱酸素剤をエージレスGPに代えて炭酸ガスを放出する脱酸素剤であるエージレス(登録商標)GT(三菱瓦斯化学社製)を使用した点を除き、実施例1と同様にして、比較例3の収納体を製造した。
上記実施例1において、炭酸ガスのバブリングによるpH調整でpHを6.8とし、脱酸素剤及び酸素検知剤を用いなかった点を除き、実施例1と同様にして、比較例4の収納体を製造した。
上記の各実施例1及び2、比較例1〜4の収納体を、40℃にて6ヶ月間保存し、保存開始1、2および6ヶ月後における薬液のpHの変動を観察した。
その結果を下記表2に示した。
上記した表1に記載の組成に従って、各成分を常温で適量の蒸留水に溶解し、溶液中に炭酸ガスをバブリングし、pHを6.6とし、0.22μmのメンブランフィルターで濾過した。濾液をポリエチレン製のプラスチック容器に500mLずつ充填し、当該容器のヘッドスペースについて窒素ガス置換を行って閉塞し、105℃/23分で高圧蒸気滅菌を行った。得られた薬液充填容器を、ガス不透過性外包材からなる二次包材である収納体に収納し、脱酸素剤(エージレスGP)及び酸素検知剤を同封した後、薬液充填容器と収納体の空間部を、窒素によって置換し、包装し、2週間室温に保存し、pHが7.1であり、ヘッドスペースの炭酸ガス濃度が10v/v%である包装体内部が完全に脱酸素された包装体を得た。
上記実施例3において、2回目の包装時に同封するエージレスGPに代えて、エージレス(登録商標)ZP(三菱瓦斯化学社製)とした点以外、実施例3と同様にして、比較例5の収納体を製造した。
上記実施例3において、2回目の包装時に同封するエージレスGPに代えて、エージレスGTとした点以外、実施例3と同様にして、比較例6の収納体を製造した。
上記実施例3において、2回目の包装時に同封するエージレスGPを同封しなかった点以外、実施例3と同様にして、比較例7の収納体を製造した。
上記の実施例3、及び比較例5〜7の収納体を、40℃にて2週間保存し、薬液のpH、薬液充填容器と収納体の空間部の炭酸ガス及び酸素濃度及び薬液充填容器のヘッドスペースの炭酸ガス及び酸素濃度を測定した。
その結果を下記表3に示した。
上記した表1に記載の組成に従って、各成分を常温で適量の蒸留水に溶解し、溶液中に炭酸ガスをバブリングし、pHを6.6とし、0.22μmのメンブランフィルターで濾過した。濾液をポリエチレン製のプラスチック容器に500mLずつ充填し、当該容器のヘッドスペースについて窒素ガス置換を行って閉塞し、105℃/25分で高圧蒸気滅菌を行った。
該薬液を充填した容器を、ガス不透過性外包材からなる二次包材である収納体に収納し、脱酸素剤(エージレスGP)及び酸素検知剤を同封した後、薬液充填容器と収納体の空間部を、当該薬液充填容器のヘッドスペースと同じ二酸化炭素濃度を有する二酸化炭素と窒素の混合ガスによって置換し、包装し、実施例4の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.5とした点を除き、実施例4と同様にして、実施例5の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.6とした点を除き、実施例4と同様にして、実施例6の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.7とした点を除き、実施例4と同様にして、実施例7の収納体を製造した。
上記実施例4において、脱酸素剤(エージレスGP)及び酸素検知剤を同封せず、この薬液充填容器と収納体の空間部を抜気して包装(脱気包装)した点を除き、実施例4と同様にして、比較例8の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.5とした点、及び脱酸素剤(エージレスGP)及び酸素検知剤を同封せず、この薬液充填容器と収納体の空間部を抜気して包装(脱気包装)した点を除き、実施例4と同様にして、比較例9の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.6とした点、及び脱酸素剤(エージレスGP)及び酸素検知剤を同封せず、この薬液充填容器と収納体の空間部を抜気して包装(脱気包装)した点を除き、実施例4と同様にして、比較例10の収納体を製造した。
上記実施例4において、炭酸ガスのバブリングによるpH調整でpHを6.7とした点、及び脱酸素剤及び酸素検知剤を使用せず、薬液充填容器をガス不透過性の収納体に収納した後脱気包装した点を除き、実施例4と同様にして、比較例11の収納体を製造した。
上記の各実施例4〜7、及び比較例8〜11の収納体を、25℃にて2週間保存し、薬液のpHおよび薬液充填容器のヘッドスペースの炭酸ガス及び酸素濃度を測定した。
その結果を下記表3に示した。
すなわち、試験例1の長期保存による安定性試験では、実施例及び比較例の収納体は、共に薬液中より収納体内部への炭酸ガスの放出が起こるため、保存開始直後にpH上昇が認められる。しかしながら、1ヶ月以降、エージレスGPの使用は他の脱酸素剤と異なり、pHの変動は、脱酸素剤を封入していない比較例にほぼ一致していた。これは、エージレスGPが他の脱酸素剤と異なり、炭酸ガスを吸収又は放出しない特徴を有するため、脱酸素剤が原因となるpHの変動を起こさず、また、長期的な安定性も高いことを示している。
なお、酸素と共に炭酸ガスを吸収するエージレスZPの使用ではpHは上昇し、炭酸ガスを放出するエージレスGTの使用では、pHが低下しており、その違いは明確であった。
Claims (4)
- 重炭酸塩を含有するpHが6.8〜7.8である薬液を充填したガス透過性プラスチック製容器を収納したガス非透過性の外包材からなる収納体であって、収納体内部の前記薬液充填容器と外包材との空間部を、薬液のpHと平衡となる炭酸ガス濃度を有するガス雰囲気とすることにより、薬液充填容器の収納前後で、薬液pH及び前記薬液充填容器内における炭酸ガス量の変動を最小限とし、該空間部に、薬液のpH及び重炭酸イオン濃度に影響を与えない脱酸素剤及び酸素探知機を収容したことを特徴とする前記重炭酸塩を含有する薬液充填容器収納体。
- 前記脱酸素剤が、炭素−炭素不飽和結合を有する架橋高分子化合物を主成分とするものである請求項1に記載の重炭酸塩を含有する薬液充填容器収納体。
- ガス非透過性の外包材における酸素透過率が0.7mL/m2/日/1気圧以下であることを特徴とする請求項1又は2に記載の重炭酸塩を含有する薬液充填容器収納体。
- 収納体内部の薬液充填容器と外包材との空間部の炭酸ガス濃度が1〜19v/v%で、且つ酸素濃度が0.1%以下である請求項1〜3のいずれかに記載の重炭酸塩を含有する薬液充填容器収納体。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006133641A JP4984033B2 (ja) | 2006-05-12 | 2006-05-12 | 重炭酸塩含有薬液を充填した容器収納体 |
KR1020070045654A KR20070109924A (ko) | 2006-05-12 | 2007-05-10 | 중탄산염 용액이 충전된 용기용 수납체 |
CNA2007101097273A CN101073534A (zh) | 2006-05-12 | 2007-05-11 | 一种用于盛装碳酸氢盐溶液的贮液器组件 |
EP07251964A EP1854492A3 (en) | 2006-05-12 | 2007-05-11 | Reservoir assembly for container holding bicarbonate solution |
US11/748,189 US20070265593A1 (en) | 2006-05-12 | 2007-05-14 | Reservoir assembly for container holding bicarbonate solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006133641A JP4984033B2 (ja) | 2006-05-12 | 2006-05-12 | 重炭酸塩含有薬液を充填した容器収納体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007301205A JP2007301205A (ja) | 2007-11-22 |
JP4984033B2 true JP4984033B2 (ja) | 2012-07-25 |
Family
ID=38370375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006133641A Active JP4984033B2 (ja) | 2006-05-12 | 2006-05-12 | 重炭酸塩含有薬液を充填した容器収納体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070265593A1 (ja) |
EP (1) | EP1854492A3 (ja) |
JP (1) | JP4984033B2 (ja) |
KR (1) | KR20070109924A (ja) |
CN (1) | CN101073534A (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5329420B2 (ja) | 2007-10-05 | 2013-10-30 | 国立大学法人 千葉大学 | 安定な炭酸水素イオン含有薬液 |
JP5370716B2 (ja) * | 2008-04-18 | 2013-12-18 | 味の素株式会社 | 炭酸水素ナトリウム含有水性製剤を充填した容器の変形防止方法 |
US20110005958A1 (en) * | 2009-07-09 | 2011-01-13 | Onpharma, Inc. | METHODS AND SYSTEMS FOR ADJUSTING THE pH OF MEDICAL BUFFERING SOLUTIONS |
US8162917B2 (en) * | 2008-05-21 | 2012-04-24 | Onpharma, Inc. | Methods and apparatus for buffering anesthetics |
US8303566B2 (en) | 2009-07-09 | 2012-11-06 | Onpharma, Inc. | Methods and apparatus for buffering parenteral solutions |
CN102574085B (zh) | 2009-07-09 | 2015-04-15 | 昂法玛公司 | 用于灭菌和容纳缓冲溶液药筒的方法和装置 |
US8585963B2 (en) * | 2009-07-09 | 2013-11-19 | Onpharma, Inc. | Methods and devices for sterilizing and holding buffering solution cartridges |
DE102015007842A1 (de) * | 2015-06-18 | 2016-12-22 | Fresenius Medical Care Deutschland Gmbh | Dialyselösung |
DE102018100462A1 (de) * | 2018-01-10 | 2019-07-11 | B. Braun Avitum Ag | Vorrichtung und Verfahren zur Bestimmung einer Aufnahmekapazität eines Sauerstoffabsorbers |
WO2020204170A1 (ja) | 2019-04-04 | 2020-10-08 | 扶桑薬品工業株式会社 | 重炭酸イオンを含有する心筋保護液の収容体、及びその製造方法 |
EP3725286A1 (en) * | 2019-04-18 | 2020-10-21 | B. Braun Melsungen AG | Medicinal product comprising a container and an aqueous liquid containing bicarbonate |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57194961A (en) * | 1981-05-12 | 1982-11-30 | Mitsubishi Gas Chemical Co | Package of deoxidizer |
US4526752A (en) * | 1982-12-16 | 1985-07-02 | Daniel Perlman | Oxygen indicator for packaging |
IT1214872B (it) * | 1984-04-06 | 1990-01-18 | Mariano Feriani | Sacca contenente due o piu'sostanze per infusione ad uso medicale, poste in scomparti separati, comprendente mezzi atti a consentire la miscelazione di tali sostanze solo al momento dell'uso. |
US5226531A (en) * | 1986-09-03 | 1993-07-13 | Seawell North America Inc. | Food packaging with gas between tensioned film and lid |
EP0301719A1 (en) * | 1987-07-27 | 1989-02-01 | CarnaudMetalbox plc | Improvements in and relating to packaging |
AU669773B2 (en) * | 1993-01-22 | 1996-06-20 | Otsuka Pharmaceutical Factory, Inc. | Bicarbonate-containing powdered medicine storage container and method of stabilizing the same medicine |
GB9310202D0 (en) * | 1993-05-18 | 1993-06-30 | Trigon Ind Ltd | A tamper evident system |
JP3243387B2 (ja) * | 1994-12-14 | 2002-01-07 | 味の素ファルマ株式会社 | 炭酸水素塩含有薬液入りプラスチック容器の収納体 |
US5698250A (en) * | 1996-04-03 | 1997-12-16 | Tenneco Packaging Inc. | Modifield atmosphere package for cut of raw meat |
CN1158984C (zh) * | 1996-06-17 | 2004-07-28 | 株式会社大塚制药工场 | 含碳酸氢盐药物溶液的包装及pH提示装置 |
JPH10211256A (ja) * | 1997-01-28 | 1998-08-11 | Jms Co Ltd | 医療用容器連結体 |
US5881879A (en) * | 1997-02-07 | 1999-03-16 | Baxter International Inc. | System for preserving and delivering gas-containing solutions |
CA2307162C (en) * | 1997-10-27 | 2006-03-21 | Otsuka Pharmaceutical Factory, Inc. | Packaged ophthalmic perfusate and cleaning fluid bag |
US6054153A (en) * | 1998-04-03 | 2000-04-25 | Tenneco Packaging Inc. | Modified atmosphere package with accelerated reduction of oxygen level in meat compartment |
JP4178334B2 (ja) * | 1998-06-02 | 2008-11-12 | 三菱瓦斯化学株式会社 | 脱酸素剤包装体 |
JP2000175989A (ja) * | 1998-12-17 | 2000-06-27 | Material Eng Tech Lab Inc | 薬液容器 |
US6461702B2 (en) * | 1999-03-15 | 2002-10-08 | River Ranch Fresh Foods-Salinas, Inc. | Coated membrane with an aperture for controlled atmosphere package |
JP3733583B2 (ja) * | 1999-10-25 | 2006-01-11 | ニプロ株式会社 | 重炭酸塩含有薬液充填容器包装体 |
US6423776B1 (en) * | 2000-05-02 | 2002-07-23 | Honeywell International Inc. | Oxygen scavenging high barrier polyamide compositions for packaging applications |
US6689438B2 (en) * | 2001-06-06 | 2004-02-10 | Cryovac, Inc. | Oxygen detection system for a solid article |
-
2006
- 2006-05-12 JP JP2006133641A patent/JP4984033B2/ja active Active
-
2007
- 2007-05-10 KR KR1020070045654A patent/KR20070109924A/ko not_active Application Discontinuation
- 2007-05-11 EP EP07251964A patent/EP1854492A3/en not_active Withdrawn
- 2007-05-11 CN CNA2007101097273A patent/CN101073534A/zh active Pending
- 2007-05-14 US US11/748,189 patent/US20070265593A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20070109924A (ko) | 2007-11-15 |
EP1854492A2 (en) | 2007-11-14 |
JP2007301205A (ja) | 2007-11-22 |
US20070265593A1 (en) | 2007-11-15 |
EP1854492A3 (en) | 2007-11-28 |
CN101073534A (zh) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4984033B2 (ja) | 重炭酸塩含有薬液を充填した容器収納体 | |
EP0760689B1 (en) | Method of manufacturing and storing solutions | |
EP1131077B2 (en) | Bicarbonate-based solution in two parts for peritoneal dialysis or as a substitution solution in continuous renal replacement therapy | |
EP0647145B1 (en) | Storing stable bicarbonate solutions | |
JP2811035B2 (ja) | 重炭酸配合液及びその収容容器 | |
JPH08164185A (ja) | 炭酸水素塩含有薬液入りプラスチック容器の収納体 | |
CN105726565A (zh) | 一种非pvc塑料包装枸橼酸钠林格注射液及其制备工艺 | |
JP2000245826A (ja) | 中性腹膜透析液 | |
JP3733583B2 (ja) | 重炭酸塩含有薬液充填容器包装体 | |
CN105769902A (zh) | 一种碳酸氢钠注射液的制造工艺 | |
JP3832458B2 (ja) | ろ過型人工腎臓用補液収容複室容器 | |
WO2020204170A1 (ja) | 重炭酸イオンを含有する心筋保護液の収容体、及びその製造方法 | |
JP7246203B2 (ja) | 血液ろ過用補充液 | |
US20060079464A1 (en) | Peritoneal dialysate containing taurine | |
JP3375518B2 (ja) | 注射剤 | |
JP6419615B2 (ja) | 腹膜透析液 | |
JP3904030B2 (ja) | 補液収容複室容器製剤 | |
JP6958265B2 (ja) | 血液ろ過用補充液 | |
JP6946952B2 (ja) | 血液ろ過用補充液 | |
JP2002308782A (ja) | 重炭酸溶液の製造方法 | |
JPH09193963A (ja) | 炭酸塩又は重炭酸塩を充填した樹脂容器の包装方法 | |
JPH08164186A (ja) | 還元糖と重炭酸を含有する一剤化された液剤の滅菌法 | |
JP4430500B2 (ja) | 炭酸水素イオン含有薬液 | |
JPH067853B2 (ja) | 加熱滅菌された血液保存液入り容器およびその製造方法 | |
WO2014162515A1 (ja) | 腹膜透析液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110128 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120328 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4984033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |